Eledon Pharmaceuticals (ELDN) Retained Earnings (2013 - 2026)
Eledon Pharmaceuticals posted quarterly Retained Earnings of -$440.2 million for Q1 2026, down 2445455.56% year-on-year from N/an in Q1 2025, and down 1834266.67% on a QoQ basis from $24000.0 in Q4 2025.
Eledon Pharmaceuticals (ELDN) has 14 years of Retained Earnings data on file, last reported at -$440.2 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 2445455.56% year-over-year to -$440.2 million; the trailing twelve-month figure through Mar 2026 stood at -$440.2 million (down 2445455.56% YoY), and the FY2025 full-year result was $24000.0, down 7.69% from the prior year.
- Retained Earnings for Q1 2026 stood at -$440.2 million, down from $24000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $102000.0 in Q3 2024 and bottomed at -$440.2 million in Q1 2026.
- The 5-year median for Retained Earnings is -$213.6 million (2023), against an average of -$214.3 million.
- The widest annual swing landed in 2024, when Retained Earnings jumped 100.04%; it then plunged 2445455.56% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$202.9 million in 2022, then sank by 57.45% to -$319.4 million in 2023, then soared by 100.01% to $26000.0 in 2024, then dropped by 7.69% to $24000.0 in 2025, then sank by 1834266.67% to -$440.2 million in 2026.
- The last three Retained Earnings figures came in at -$440.2 million (Q1 2026), $24000.0 (Q4 2025), and -$390.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | -440.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -440.20 Mn |
| Dec 31, 2025 | 24,000.00 |
| Sep 30, 2025 | -390.76 Mn |
| Jun 30, 2025 | -373.30 Mn |
| Mar 31, 2025 | -18,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | 102,000.00 |
| Jun 30, 2024 | -387.94 Mn |
| Mar 31, 2024 | -343.03 Mn |
| Dec 31, 2023 | -319.40 Mn |
| Sep 30, 2023 | -289.30 Mn |
| Jun 30, 2023 | -279.40 Mn |
| Mar 31, 2023 | -213.60 Mn |
| Dec 31, 2022 | -202.87 Mn |
| Sep 30, 2022 | -144.48 Mn |
| Jun 30, 2022 | -134.00 Mn |
| Mar 31, 2022 | -124.76 Mn |
| Dec 31, 2021 | -114.90 Mn |
| Sep 30, 2021 | -106.10 Mn |
| Jun 30, 2021 | -96.30 Mn |
| Mar 31, 2021 | -88.89 Mn |
| Dec 31, 2020 | -80.39 Mn |
| Sep 30, 2020 | -74.49 Mn |
| Jun 30, 2020 | -68.35 Mn |
| Mar 31, 2020 | -65.76 Mn |
| Dec 31, 2019 | -57.58 Mn |
| Sep 30, 2019 | -53.44 Mn |
| Jun 30, 2019 | -50.55 Mn |
| Mar 31, 2019 | -46.45 Mn |
| Dec 31, 2018 | -41.57 Mn |
| Sep 30, 2018 | -37.00 Mn |
| Jun 30, 2018 | -33.50 Mn |
| Mar 31, 2018 | -30.31 Mn |
| Dec 31, 2017 | -27.51 Mn |
| Sep 30, 2017 | -25.40 Mn |
| Jun 30, 2017 | -22.43 Mn |
| Mar 31, 2017 | -173.26 Mn |
| Dec 31, 2016 | -14.39 Mn |
| Sep 30, 2016 | 3,000.00 |
| Jun 30, 2016 | 6,000.00 |
| Mar 31, 2016 | -5,000.00 |
| Dec 31, 2015 | -55,000.00 |
| Sep 30, 2015 | -120.42 Mn |
| Jun 30, 2015 | -2,000.00 |
| Mar 31, 2015 | -99.61 Mn |
| Dec 31, 2014 | -86.35 Mn |
| Sep 30, 2014 | -80.14 Mn |
| Dec 31, 2013 | -63.06 Mn |